on BioVersys AG
BioVersys AG Annual General Meeting Yields Positive Outcomes
BioVersys AG announced the outcomes of its Annual General Meeting (AGM) of Shareholders held on June 27, 2025. A noteworthy 55.4% of the company's share capital was represented. All agenda items secured a majority vote in favor.
The AGM approved the 2024 Annual Report, re-elected key board members including Seng Chin Mah as Chairman, and elected Ulrik Schulze as a new board member. Additionally, shareholders endorsed an amendment to the company's capital structure, enhancing the board’s operational flexibility for strategic initiatives.
Chairman Seng Chin Mah expressed gratitude to shareholders for their unwavering support as the company approaches the final development phase for BV100 and progresses with alpibectir and preclinical projects. He also welcomed Dr. Ulrik Schulze to the board.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all BioVersys AG news